|
|
 |
|
Viewing report
|
|
|
|
US Neuropathic Pain 2008 - 4th Edition: Market Potential Through 2018
WWMR, Sep 2008, Pages: 151
This new EP Publications report:
- Provides an epidemiological forecast for key conditions associated with neuropathic pain in the US market in 2008, 2013, and 2018
- Forecasts the potential value of the neuropathic pain market for ten indications through 2018
- Presents expert analysis of the commercial potential and key differences among products in development for the treatment of neuropathic pain
- Describes the critical factors driving neuropathic pain market growth through 2018
New for 2008 report:
- Two New Indications:
- - Fibromyalgia
- - Neuropathic Cancer Pain
- Insights based upon Pain Clinic Monitor, profiling neuropathic pain conditions
A Complex Market of Diverse Needs
Neuropathic pain (NP) can have chronic, debilitating impact on the lives of patients with a variety of conditions, including low back pain, diabetes, herpes, trigeminal neuralgia, HIV/AIDS, neuropathic cancer pain and fibromyalgia. Many patients and their physicians fail to realize the neuropathic nature of some patients’ pain, including severe burning, stinging, and shooting pain. This general lack of awareness is largely due to the complicated nature of the onset of NP, difficulty in confirming diagnoses, and the lack of effective treatments.
An Opportunity to Meet Unmet Need for Therapy
By 2018, there will be approximately 6 million individuals in US suffering from major NP conditions.
Given this substantial patient population, NP has received particular attention in recent years due to its relative resistance to conventional analgesic therapies. Importantly, many analgesic drugs, from nonsteroidal anti-inflammatory drugs to strong opiates, have proven to be either ineffective or to provide only limited relief. More pharmacological therapies have been approved specifically for the treatment of NP in recent years.
There is still a great need to develop novel therapies that are safe and effective. Recent research elucidating the mechanisms of NP has provided new targets for pharmacological interventions that have captured the attention of the pharmaceutical industry.
Report Objectives & Methodology
This report provides an overview for ten major conditions causing NP in the US market.
This report also summarizes current understanding of NP mechanisms, and highlights promising targets for drug development. Also reviewed are new treatments already in development that offer the promise of improved pain management of NP in the near future. Models representing patient populations and the commercial value (USD) of this market in 2008, 2013, and 2018 are presented.
These models describe the important features of key conditions associated with NP:
- Neuropathic back pain
- Diabetic neuropathy
- Complex regional pain syndrome
- HIV/AIDS neuropathy
Post-herpetic neuralgia:
- Phantom limb pain
- Spinal cord injury
- Trigeminal neuralgia
- Fibromyalgia
- Neuropathic cancer pain
Expert analysis and commentary describing the future NP market are based on:
- Pain Clinic Monitor, profiling neuropathic pain conditions
- Comprehensive analysis of uses for specific conditions, including estimations of prescription size, number of refills, and cost
- Evaluation of drugs in the NP drug pipeline, with conclusions on the future directions in treatment
- In-depth analysis of the medical literature, including treatment review articles, medical textbooks, epidemiology studies, and clinical studies
- Thorough review of country-specific and overall trends Market and patient population forecasts are based on a consensus developed from industry experience, clinician input, and analysis of secondary sources.
US Neuropathic Pain report will allow pharmaceutical and biotechnology executives to:
- Compare the epidemiology of neuropathic pain, including projected growth rates, by indication
- Recognize the specific conditions associated with neuropathic pain that have high market potential in the next 10 years
- Target specific patient populations who will benefit most from drugs in the neuropathic pain pipeline
- Anticipate upcoming competitors and product licensing opportunities
- Understand the type and level of unmet need in the US neuropathic pain market
- Recognize the impact of special market dynamics, including potential off-label usage, on product uptake forecasts
|
|
|
|
